Compass Therapeutics’ stock rating at Wedbush is downgraded amid concerns that the U.S. Food and Drug Administration (FDA) is seeking an additional clinical trial for the company’s lead asset. The move reflects investor uncertainty about the potential impact on the timeline and path to regulatory progress.
Both outlets connect the downgrade to the FDA’s request, indicating that regulatory requirements are central to the market reaction. While Seeking Alpha frames the decision around the FDA seeking more trial data for the lead product, Investing.com similarly emphasizes the rating change tied to trial concerns. Neither source provides detailed study design, endpoints, or timing in the information provided here, so the practical implications are presented mainly in terms of added uncertainty rather than specific revised milestones.
